All of the adverse events that occurred in these individuals were introduced into a database and we established the correlation involving the regimen and each side effect, the grade of each side effect as well as its management. Final results A total of 87 sufferers had been followed, using a median age of 63 years (IQR 54?0 years) and 47 males. 36 sufferers (41.four ) reported at least one clinical adverse occasion. Essentially the most prevalent had been fatigueBMC Infectious Diseases 2016, 16(Suppl four):Web page 44 ofConclusions The fibrosis cannot be normally correctly determined by FibroMax; it’s essential to work with other alternative test for an correct diagnosis of cirrhosis. In addition, even the tests manufacturer from BioPredictive recommends that a fibrotest score with a value greater than 0.60 can be interpreted as serious fibrosis and must be treated get GW433908G urgently. A33 Serious reactivation of chronic hepatitis B just after discontinuation of nucleos(t)ide analogues ?a case series Cristina Popescu1,2, Alina Orfanu1,two, Anca Leutean1, Alexandra Badea1, Laureniu Stratan1, Remulus Catan1,2, Ctlin Tilican1,two, Victoria Aram1,2 1 National Institute for Infectious Diseases “Prof. Dr. Matei Bal”, Bucharest, Romania; 2Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Correspondence: Alina Orfanu ([email protected]) BMC Infectious Illnesses 2016, 16(Suppl 4):A33 Background Nucleos(t)ide analogues (NAs) understand a appropriate suppression of viral replication in chronic hepatitis B (HBV), but 146167210390822 a negligible immune manage, so a lifelong therapy is needed. The highest threat following therapy discontinuation, even in individuals who achieved undetectable viral load (VL), would be the viral reactivation. Reactivation flares appear in ten of circumstances soon after therapy cessation and are associated with jaundice, hepatocytolysis and high VL. Some circumstances can create fulminant hepatitis with higher mortality rate. Methods We present a series of 3 cases of viral reactivation following discontinuation of Entecavir (ETV), administered for chronic HBV. Results In 2015?016, 3 patients known with chronic HBV had been admitted in our department for jaundice and ALT increase. The first case is a young woman, pregnant in 24 weeks, under ETV for 4 years, with negative HBeAg and undetectable VL, who decided to quit therapy when she found the pregnancy. Six months later she was admitted in our clinic for essential hepatocytolysis. The biological exams revealed: ALT > 20 x upper limit of normal (ULN), good HBeAg, HBV VL of 9 log IU/mL, normal prothrombin concentration and mild hyperbilirubinemia. The patient received off label lamivudine with slow decrease of ALT and VL of 2 log IU/mL at delivery. ETV therapy was reintroduced soon after delivery, with favorable outcome. The second case is really a young man who discontinued ETV simply because he lost his health-related insurance coverage. In the course of antiviral therapy he had typical ALT and undetectable VL. 5 months later, he presented ALT 5xULN, jaundice and high VL. The patient renewed his insurance coverage and ETV was reinitiated, with excellent outcome. The final patient, a 28 yearold man is still hospitalized. He was below ETV for 6 years with good biological outcome, after a prior therapy with peginterferon. In January 2016, he stopped ETV by himself and in August he was admitted in our clinic for jaundice and vomiting. The tests showed ALT 60xULN, hyperbilirubinemia (16 mg/dL), good HBeAg jir.2012.0140 and lower of prothrombin concentration and fibrinogen. The therap.